Management of Severe and Severe/Complicated Clostridoides difficile Infection Using Sequential Fecal Microbiota

Abbas Hatim Rupawala1, Darrel Gachette2, Mena Bakhit3

  • 1Division of Gastroenterology, Department of Internal Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Insights

Serial fecal microbiota transplant (FMT) via retention enema showed limited sustained cure for severe Clostridoides difficile infection (CDI). While many patients improved initially, only 5 of 15 achieved a 30-day cure, with 4 experiencing serious adverse events.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Clostridoides difficile infection (CDI) poses a significant challenge, particularly severe or complicated cases unresponsive to standard antibiotic therapy.
  • Recurrent CDI necessitates exploring alternative and effective treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of serial fecal microbiota transplant (FMT) administered via retention enema for patients with refractory severe or severe/complicated CDI.

Main Methods:

  • A cohort of 15 patients with severe/complicated CDI, failing at least 48 hours of antibiotics, received serial FMT by retention enema.
  • Patient outcomes, including sustained cure at 30 days and adverse events, were monitored.

Main Results:

  • Initial clinical improvement was observed in the majority of patients following FMT.
  • However, only 5 out of 15 patients achieved a sustained cure at the 30-day follow-up.
  • Four patients experienced serious adverse events during the study period.

Conclusions:

  • Serial FMT via retention enema demonstrates potential for initial symptom relief in severe CDI.
  • The treatment shows limited efficacy in achieving sustained cure rates at 30 days for this patient population.
  • Further research is warranted to optimize FMT protocols and assess long-term safety for refractory CDI.

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
302
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
431
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
483
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
310